NZS Capital LLC Purchases 51,483 Shares of Repligen Corporation $RGEN

NZS Capital LLC increased its position in shares of Repligen Corporation (NASDAQ:RGEN) by 35.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 196,777 shares of the biotechnology company’s stock after buying an additional 51,483 shares during the quarter. NZS Capital LLC’s holdings in Repligen were worth $26,303,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in shares of Repligen in the 1st quarter worth $262,000. Jones Financial Companies Lllp raised its holdings in Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock worth $814,000 after buying an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Repligen by 16.8% in the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares in the last quarter. AlphaQuest LLC acquired a new position in shares of Repligen during the second quarter valued at about $104,000. Finally, Hantz Financial Services Inc. increased its position in shares of Repligen by 2,663.6% during the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 293 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on RGEN shares. UBS Group dropped their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Wells Fargo & Company lowered their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. KeyCorp restated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Barclays cut their target price on Repligen from $200.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 25th. Finally, Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus price target of $174.58.

Repligen Stock Performance

Shares of Repligen stock opened at $123.06 on Wednesday. The business’s fifty day simple moving average is $152.50 and its 200 day simple moving average is $147.09. The company has a current ratio of 8.37, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $175.77. The firm has a market capitalization of $6.93 billion, a P/E ratio of 144.78, a price-to-earnings-growth ratio of 2.43 and a beta of 1.14.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The company had revenue of $197.91 million for the quarter, compared to the consensus estimate of $192.23 million. During the same period in the previous year, the firm earned $0.44 EPS. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.